Homocistein
IUPAC ime
2-Amino-4-sulfanilbutanska kiselina
Identifikacija
CAS registarski broj
454-29-5 Y , 6027-13-0 L -isomer) Y
PubChem [1] [2] 778
ChemSpider [3] 757 Y
UNII
0LVT1QZ0BA Y
EC-broj
207-222-9
KEGG [4] C05330
ChEBI
17230
ChEMBL [5] CHEMBL310604 Y
Jmol -3D slike
Slika 1
InChI=1S/C4H9NO2S/c5-3(1-2-8)4(6)7/h3,8H,1-2,5H2,(H,6,7) Y Y
InChI=1/C4H9NO2S/c5-3(1-2-8)4(6)7/h3,8H,1-2,5H2,(H,6,7)
Svojstva
Molekulska formula
C4 H9 NO2 S
Molarna masa
135,18 g/mol
Y (šta je ovo?)
(verifikuj)
Ukoliko nije drugačije napomenuto, podaci se odnose na standardno stanje (25 °C, 100 kPa) materijala
Infobox references
Homocistein je neproteinska aminokiselina . On je homolog aminokiseline cisteina , od koje se razlikuje po dodatnoj metilenskoj (-CH2 -) grupi. On se biosintetiše iz metionina uklanjanjem terminalne Cε metil grupe. Homocistein se može reciklisati u metionin ili konvertovati u cistein uz pomoć B-vitamina.
Detekcija visokih nivoa homocisteina je povezana sa kardiovaskularnim bolesima, mada snižavanje nivoa homocisteina ne poboljšava ishod oboljenja.[6] [7] [8] [9] [10]
↑ Li Q, Cheng T, Wang Y, Bryant SH (2010). „PubChem as a public resource for drug discovery.” . Drug Discov Today 15 (23-24): 1052-7. DOI :10.1016/j.drudis.2010.10.003 . PMID 20970519 . edit ↑ Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry 4 : 217-241. DOI :10.1016/S1574-1400(08)00012-1 . ↑ Hettne KM, Williams AJ, van Mulligen EM, Kleinjans J, Tkachenko V, Kors JA. (2010). „Automatic vs. manual curation of a multi-source chemical dictionary: the impact on text mining” . J Cheminform 2 (1): 3. DOI :10.1186/1758-2946-2-3 . PMID 20331846 . edit ↑ Joanne Wixon, Douglas Kell (2000). „Website Review: The Kyoto Encyclopedia of Genes and Genomes — KEGG” . Yeast 17 (1): 48–55. DOI :10.1002/(SICI)1097-0061(200004)17:1<48::AID-YEA2>3.0.CO;2-H . ↑ Gaulton A, Bellis LJ, Bento AP, Chambers J, Davies M, Hersey A, Light Y, McGlinchey S, Michalovich D, Al-Lazikani B, Overington JP. (2012). „ChEMBL: a large-scale bioactivity database for drug discovery”. Nucleic Acids Res 40 (Database issue): D1100-7. DOI :10.1093/nar/gkr777 . PMID 21948594 . edit ↑ Martí-Carvajal AJ, Solà I, Lathyris D, Salanti G (2009). Martí-Carvajal, Arturo J. ur. „Homocysteine lowering interventions for preventing cardiovascular events”. Cochrane Database Syst Rev (4): CD006612. DOI :10.1002/14651858.CD006612.pub2 . PMID 19821378 . ↑ Martí-Carvajal, AJ; Solà, I; Lathyris, D; Salanti, G. (2009-10-07). „Homocysteine lowering interventions for preventing cardiovascular events.”. Cochrane database of systematic reviews (Online) (4): CD006612. DOI :10.1002/14651858.CD006612.pub2 . PMID 19821378 . ↑ Jardine, MJ; Kang, A; Zoungas, S; Navaneethan, SD; Ninomiya, T; Nigwekar, SU; Gallagher, MP; Cass, A; Strippoli, G; Perkovic, V. (2012-06-13). „The effect of folic acid based homocysteine lowering on cardiovascular events in people with kidney disease: systematic review and meta-analysis.” . BMJ (Clinical research ed.) 344 : e3533. PMC 3374481 . PMID 22695899 . ↑ Vizzardi, E; Bonadei, I; Zanini, G; Frattini, S; Fiorina, C; Raddino, R; Dei Cas, L. (January 2009). „Homocysteine and heart failure: an overview.”. Recent patents on cardiovascular drug discovery 4 (1): 15–21. PMID 19149701 . ↑ Ahmadieh, H; Arabi, A. (October 2011). „Vitamins and bone health: beyond calcium and vitamin D.” . Nutrition Reviews 69 (10): 584–98. DOI :10.1111/j.1753-4887.2011.00372.x . PMID 21967159 .
, 6027-13-0 (L-isomer) 
